Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE Technology
Portfolio Pulse from Benzinga Newsdesk
Acumen Pharmaceuticals, Inc. and Halozyme have entered a global collaboration and license agreement to develop a subcutaneous formulation of ACU193 with ENHANZE technology.
November 06, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acumen Pharmaceuticals has entered a collaboration with Halozyme to develop a new formulation of ACU193.
The collaboration with Halozyme for the development of a new formulation of ACU193 could potentially lead to a new revenue stream for Acumen Pharmaceuticals. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Halozyme has entered a collaboration with Acumen Pharmaceuticals to develop a new formulation of ACU193.
The collaboration with Acumen Pharmaceuticals for the development of a new formulation of ACU193 could potentially lead to a new revenue stream for Halozyme. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100